Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin. ⋯ AstraZeneca and Bristol-Myers Squibb.
-
Multicenter Study
Surrogate decision makers' interpretation of prognostic information: a mixed-methods study.
Little is known about why surrogate decision makers for patients with advanced illness often have overly optimistic expectations about prognosis. ⋯ National Heart, Lung, and Blood Institute.